Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes
2016 ASCO Annual Meeting
Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506). To see the French language version of this discussion, click here.
Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion (Abstract LBA2000).
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses findings of this phase III study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (Abstract 4003).
Heinz-Josef Lenz, MD, of the University of Southern California, and Jonathan R. Strosberg, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discuss efficacy and safety results in patients with midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 4005).
Nagi S. El-Saghir, MD, of the American University of Beirut, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss oncology from an international point of view.
Maria Clemence Schwaederle, PharmD, of the University of California, San Diego, discusses an analysis of 13,203 patients in phase I clinical trials, which showed that a personalized strategy led to improved response rate and progression-free survival (Abstract 11520).
